Format

Send to

Choose Destination
Oncol Lett. 2016 May;11(5):2981-2986. Epub 2016 Mar 17.

Low-dose bevacizumab induces radiographic regression of vestibular schwannomas in neurofibromatosis type 2: A case report and literature review.

Author information

1
Department of Neurosurgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China; Department of Neurosurgery, Binzhou Medical University Hospital, Binzhou, Shandong 256600, P.R. China.
2
Department of Neurosurgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.
3
Department of Nuclear Medicine, Binzhou Medical University Hospital, Binzhou, Shandong 256600, P.R. China.
4
Department of Neurosurgery, Binzhou Medical University Hospital, Binzhou, Shandong 256600, P.R. China.

Abstract

The current case study aimed to explore the efficacy of a low-dose bevacizumab regimen in inhibiting tumor growth and minimizing adverse effects. A 55-year-old man with neurofibromatosis type 2 (NF2) suffered bilateral vestibular schwannomas (VS) measuring 5.25 and 2.54 cm3 on the left and right, respectively. His capacity for bilateral language recognition was impaired. However, the patient refused microsurgical tumor resection and gamma knife therapy. Low-dose bevacizumab regimen (3.3-2.2 mg/kg every 2-4 weeks) was administered by intravenous injection for ~1.5 years to inhibit tumor growth and avoid further deterioration of hearing. Compared with baseline measurements prior to treatment, the bilateral VS regressed to 3.59 cm3 (68%) and 2.08 cm3 (82%) on the left and right, respectively. No hearing improvement was detected; however, the patient subjectively experienced a significant hearing improvement as his ability to communicate with people and distinguish voices was restored. No adverse effects were observed. Bevacizumab provides an alternative treatment option for those who refuse surgical intervention. Given the adverse effects commonly induced by bevacizumab, the use of a low-dose regimen would appear to be promising with regard to tumor regression and hearing preservation for patients with VS in NF2. However, the minimum dose required to sustain a response to bevacizumab in NF2 patients remains unknown. Finding the minimum effective dose sufficient to sustain hearing and/or volumetric response for individual patients is required.

KEYWORDS:

bevacizumab; neurofibromatosis type 2; vascular endothelial growth factor; vestibular schwannomas

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center